S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.55%)
BABA   74.68 (-2.68%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.71%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+6.86%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Cocrystal Pharma Stock Price, News & Analysis (NASDAQ:COCP)

$1.85
+0.01 (+0.54%)
(As of 11/29/2023 ET)
Compare
Today's Range
$1.70
$1.90
50-Day Range
$1.46
$2.13
52-Week Range
$1.38
$3.29
Volume
14,460 shs
Average Volume
46,062 shs
Market Capitalization
$18.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Cocrystal Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
548.6% Upside
$12.00 Price Target
Short Interest
Healthy
0.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Cocrystal Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.00) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

406th out of 949 stocks

Pharmaceutical Preparations Industry

180th out of 435 stocks


COCP stock logo

About Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

COCP Stock Price History

COCP Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Recap: Cocrystal Pharma Q3 Earnings
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Analyst Ratings for Cocrystal Pharma
Cocrystal Pharma (COCP) Receives a Buy from H.C. Wainwright
Noble Financial Keeps Their Buy Rating on Cocrystal Pharma (COCP)
H.C. Wainwright Keeps Their Buy Rating on Cocrystal Pharma (COCP)
See More Headlines
Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+566.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.01 million
Cash Flow
$0.17 per share
Book Value
$3.02 per share

Miscellaneous

Free Float
7,624,000
Market Cap
$18.31 million
Optionable
Not Optionable
Beta
1.24
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Roger D. Kornberg Ph.D. (Age 76)
    Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
    Comp: $125k
  • Dr. Sam Lee Ph.D. (Age 63)
    Co-Founder, Co-CEO & President
    Comp: $521.38k
  • Mr. James J. Martin CPA (Age 56)
    M.B.A., Co-CEO, CFO & Corporate Secretary
    Comp: $521.38k














COCP Stock Analysis - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings
or view top-rated stocks.

What is Cocrystal Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 548.6% from the stock's current price.
View analysts price targets for COCP
or view top-rated stocks among Wall Street analysts.

How have COCP shares performed in 2023?

Cocrystal Pharma's stock was trading at $1.95 at the beginning of the year. Since then, COCP stock has decreased by 5.1% and is now trading at $1.85.
View the best growth stocks for 2023 here
.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 9,800 shares, an increase of 84.9% from the October 31st total of 5,300 shares. Based on an average daily volume of 27,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are short sold.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our COCP earnings forecast
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.48).

When did Cocrystal Pharma's stock split?

Shares of Cocrystal Pharma reverse split on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:COCP) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -